Compare Arko Corp. (ARKO) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arko Corp. vs Gilead Sciences, Inc. — how do they compare? Arko Corp. trades at $4.5 (market cap $499.23M), while Gilead Sciences, Inc. trades at $136.85 (market cap $168.47B). The key difference: Gilead Sciences, Inc. is far larger — about 337.5× Arko Corp.'s market cap, and Arko Corp. pays the higher dividend (2.7%). Which is the better fit depends on your goals.
| ARKO | GILD | |
|---|---|---|
Market Cap | $499.23M | $168.47B |
Sector | Consumer Cyclical | Health |
52-Week High | $8.64 | $155.80 |
52-Week Low | $3.82 | $110.56 |
Enterprise Value | $2.68B | $191.54B |
Dividend Yield | 2.7% | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKO trades at $4.46, down 5.11% on the day, reflecting bearish technical signals and recent earnings miss. The company maintains a low P/S ratio of 0.06 and pays consistent dividends, but faces declining revenue and thin net margins. Recent news highlights weak Q2 2026 results and softer retail demand, with analysts holding a neutral stance.
Outlook remains cautious due to earnings volatility and competitive pressures, though the dividend yield and low valuation offer some value. Key risks include consumer spending sensitivity and high debt levels, requiring close monitoring of margin defense strategies and fuel pricing discipline for recovery.
Gilead Sciences (GILD) trades at $135.78, up 2.04% on the day, with a bullish technical signal and strong support at $134. Recent Q2 2026 earnings beat revenue estimates despite a net loss, driven by 10% base business growth from HIV drugs like Biktarvy. The company raised its full-year sales outlook, but faces a negative net income margin of -10.64% and elevated debt levels.
The outlook is mixed: robust HIV franchise growth and a 67% analyst buy rating support upside to the $151.22 consensus target, but acquisition costs, patent cliff risks, and volatile cash flows pose challenges. Investment appeal hinges on pipeline execution offsetting margin pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arko Corp.
ARKO Corp operates as a holding company. The company, through its subsidiaries, owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in three segments: Retail, Wholesale, and GPM Petroleum. The company derives the majority of its revenue from retail and wholesale distribution of fuel.
Read more on ARKO →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
